CN113332374A - Application of traditional Chinese medicine composition in preparation of medicine for inhibiting endometrial hyperplasia - Google Patents
Application of traditional Chinese medicine composition in preparation of medicine for inhibiting endometrial hyperplasia Download PDFInfo
- Publication number
- CN113332374A CN113332374A CN202010099158.4A CN202010099158A CN113332374A CN 113332374 A CN113332374 A CN 113332374A CN 202010099158 A CN202010099158 A CN 202010099158A CN 113332374 A CN113332374 A CN 113332374A
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 201000006828 endometrial hyperplasia Diseases 0.000 title claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title description 17
- 210000000582 semen Anatomy 0.000 claims abstract description 30
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 24
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 24
- 235000008434 ginseng Nutrition 0.000 claims abstract description 24
- 241000096284 Gynochthodes officinalis Species 0.000 claims abstract description 23
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 23
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 23
- 241000005787 Cistanche Species 0.000 claims abstract description 20
- 210000001320 hippocampus Anatomy 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- 238000002156 mixing Methods 0.000 claims description 31
- 235000013399 edible fruits Nutrition 0.000 claims description 28
- 241000208340 Araliaceae Species 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 18
- 241001278833 Rosa laevigata Species 0.000 claims description 14
- 235000000661 Rosa laevigata Nutrition 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 14
- 240000000233 Melia azedarach Species 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 13
- 241000241550 Cyathula Species 0.000 claims description 12
- 210000003056 antler Anatomy 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 240000007371 Cuscuta campestris Species 0.000 claims description 9
- 241000893536 Epimedium Species 0.000 claims description 9
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 9
- 244000182216 Mimusops elengi Species 0.000 claims description 9
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 9
- 240000006079 Schisandra chinensis Species 0.000 claims description 9
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 9
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 9
- 235000018905 epimedium Nutrition 0.000 claims description 9
- 235000018645 Allium odorum Nutrition 0.000 claims description 8
- 244000003377 Allium tuberosum Species 0.000 claims description 8
- 235000005338 Allium tuberosum Nutrition 0.000 claims description 8
- 206010020718 hyperplasia Diseases 0.000 claims description 7
- 244000014047 Polianthes tuberosa Species 0.000 claims description 6
- 235000016067 Polianthes tuberosa Nutrition 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000469 ethanolic extract Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 101000831205 Danio rerio Dynein axonemal assembly factor 11 Proteins 0.000 claims description 5
- 102100024282 Dynein axonemal assembly factor 11 Human genes 0.000 claims description 5
- 241001559542 Hippocampus hippocampus Species 0.000 claims description 5
- 101000831210 Homo sapiens Dynein axonemal assembly factor 11 Proteins 0.000 claims description 5
- 244000241838 Lycium barbarum Species 0.000 claims description 5
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 5
- 235000015468 Lycium chinense Nutrition 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 4
- 241000336315 Cistanche salsa Species 0.000 claims description 2
- 244000235659 Rubus idaeus Species 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 240000007651 Rubus glaucus Species 0.000 abstract description 17
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 14
- 239000000686 essence Substances 0.000 description 13
- 239000000262 estrogen Substances 0.000 description 8
- 229940011871 estrogen Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 235000009200 high fat diet Nutrition 0.000 description 7
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 210000004907 gland Anatomy 0.000 description 5
- 241000427159 Achyranthes Species 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010046764 Uterine atrophy Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000009164 estrogen replacement therapy Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 210000001703 glandular epithelial cell Anatomy 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 239000003075 phytoestrogen Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 231100001042 uterine atrophy Toxicity 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000212948 Cnidium Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000022483 simple endometrial hyperplasia Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides application of a traditional Chinese medicine composition in preparing a medicine for inhibiting endometrial hyperplasia, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 150-350 parts of semen cuscutae, 100-200 parts of fructus lycii, 30-60 parts of fructus schisandrae, 20-50 parts of fructus cnidii, 20-50 parts of fructus rosae laevigatae, 20-50 parts of semen allii tuberosi, 20-50 parts of morinda officinalis, 20-50 parts of cistanche, 30-60 parts of radix rehmanniae recen, 20-50 parts of radix cyathulae, 40-100 parts of herba epimedii, 20-50 parts of raspberry, 15-35 parts of ginseng, 10-25 parts of cornu cervi pantotrichum, 15-35 parts of hippocampus and 15-35 parts of fructus toosendan.
Description
Technical Field
The invention relates to a new application of a traditional Chinese medicine composition, in particular to an application of the traditional Chinese medicine composition in a medicine for inhibiting endometrial hyperplasia.
Background
Endometrial hyperplasia (Endometrial hyperplasia EH) refers to the proliferation of Endometrial glands or stroma caused by increased estrogen in the body, and is a common gynecological disease. Different degrees and types of hyperplasia ultimately lead to different risks of endometrial cancer, and accurate diagnosis and appropriate treatment can reduce the risk of transformation of such precancerous lesions into cancer.
The classification into type 3 is based on the structural morphology change of glands and the presence or absence of glandular epithelial cell heterogeneity: pure hyperplasia: physiologic endometrial responses due to long-term estrogen stimulation without progesterone antagonism. The stroma and gland proliferate simultaneously without gland crowding, and the shape of glandular epithelium has no heterogeneity. ② compound hyperplasia: the gland of the lesion area is crowded, the stroma is obviously reduced, and the abnormal shape of glandular epithelial cells is absent. ③ atypical hyperplasia: glandular epithelium is heterogeneous, belongs to intraepithelial tumors of endometrium, and is divided into light, medium and heavy according to the degree of pathological changes.
The etiological factors of endometrial hyperplasia are not well understood, but the following phenomena and facts indicate that long-term estrogen stimulation is the major etiological factor. Anovulation may occur in adolescent girls, perimenopausal women, or in disorders of some of the hypothalamic-pituitary-ovarian axis, polycystic ovarian syndrome, etc. The endometrium is continuously affected by estrogen for a long time, is free of progestational hormone resistance, lacks the transformation of a periodic secretory period and is in a hyperplastic state. Endometrial hyperplasia was observed in 20% of women who received postmenopausal Estrogen Replacement Therapy (ERT) for 1 year with estrogen alone. Endometrial hyperplasia can also be observed in patients with post-menopausal, advanced breast cancer who have been taking Tamoxifen (TAM) for a long period of time. Tamoxifen has weak estrogen-like action.
The medicine contains a plurality of phytoestrogens, which are phenolic cyclic molecules with a structure similar to that of the estrogens, and can play estrogen-like effects without corresponding side effects. Experiments prove that the medicine can inhibit endometrial hyperplasia.
Disclosure of Invention
The medicine of the invention is prepared from eight subclasses of medicines, namely medlar and dodder for tonifying the kidney and replenishing vital essence, schisandra chinensis, raspberry and cherokee rose for tonifying the kidney and consolidating the essence, and common cnidium fruit and Chinese chive seed for tonifying yang and replenishing vital essence. Only Chuan Lian Zi is not good at tonifying but good at moving qi, so in qi-regulating herbs, Chuan Lian Zi is good at regulating qi of liver and kidney in lower energizer and tonifying kidney essence, so it has the action of tonifying without stagnation. According to the theory of essence deficiency in Huangdi's inner Jing, the tonifying taste and the theory of the behaviour of the leaf Tianshi as essence filling, the Bazi kidney-tonifying capsule is combined with the deer horn and the sea horse which are blood and meat-conditioned, so as to tonify the kidney and fill the essence, and the Bazi kidney-tonifying capsule is combined with the child drugs to complement each other. Cornu Cervi Pantotrichum, Ben Cao gang mu, is called "producing essence and replenishing marrow, nourishing blood and tonifying yang, strengthening tendons and bones" and is the essential herb for replenishing kidney essence; the hippocampus invigorates kidney and replenishes essence, and harmonizes qi and blood. On the basis of the medicine for tonifying kidney essence, the medicine is combined with radix rehmanniae for nourishing kidney yin, epimedium herb, morinda officinalis and cistanche for assisting kidney yang so as to regulate yin and yang; ginseng radix for invigorating primordial qi (inspired by medical science) is added to tonify true qi and promote blood circulation; achyranthes root, radix Achyranthis bidentatae, as a kind of medicine, can tonify liver and kidney, and lead various herbs downward, as in Wei Jie Zhong Can xi Lu (records of Yi Xue Zhong Can xi): original achyranthes root is a tonic product and good at directing qi and blood downward, which is intended to go downward and always used as a channel-leading product, meanwhile, achyranthes root has the function of smoothing collaterals and qi, and ginseng and achyranthes root are used as tonics to promote the circulation of drugs. The medicines are combined to play the roles of tonifying kidney essence, regulating yin and yang, tonifying kidney qi and promoting blood circulation to achieve the comprehensive functions of tonifying kidney and dredging collaterals.
The invention provides application of a traditional Chinese medicine composition in preparing a medicine for inhibiting endometrial hyperplasia, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 150-350 parts of semen cuscutae, 100-200 parts of fructus lycii, 30-60 parts of fructus schisandrae, 20-50 parts of fructus cnidii, 20-50 parts of fructus rosae laevigatae, 20-50 parts of semen allii tuberosi, 20-50 parts of morinda officinalis, 20-50 parts of cistanche, 30-60 parts of radix rehmanniae recen, 20-50 parts of radix cyathulae, 40-100 parts of herba epimedii, 20-50 parts of raspberry, 15-35 parts of ginseng, 10-25 parts of cornu cervi pantotrichum, 15-35 parts of hippocampus and 15-35 parts of fructus toosendan.
The preferred traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 150 parts of semen cuscutae, 200 parts of fructus lycii, 30 parts of fructus schizandrae, 50 parts of fructus cnidii, 20 parts of fructus rosae laevigatae, 20 parts of semen allii tuberose, 50 parts of morinda officinalis, 20 parts of herba cistanche, 30 parts of radix rehmanniae recen, 50 parts of radix cyathulae, 40 parts of herba epimedii, 50 parts of raspberry, 15 parts of ginseng, 25 parts of cornu cervi pantotrichum, 15 parts of hippocampus and 35 parts of fructus toosendan.
The preferred traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 350 parts of semen cuscutae, 100 parts of fructus lycii, 60 parts of fructus schizandrae, 20 parts of fructus cnidii, 50 parts of fructus rosae laevigatae, 50 parts of semen allii tuberose, 20 parts of morinda officinalis, 50 parts of herba cistanche, 60 parts of radix rehmanniae recen, 20 parts of radix cyathulae, 100 parts of herba epimedii, 20 parts of raspberry, 35 parts of ginseng, 10 parts of cornu cervi pantotrichum, 35 parts of hippocampus and 15 parts of fructus toosendan.
The preferred traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 250 parts of semen cuscutae, 138 parts of fructus lycii, 46 parts of fructus schizandrae, 35 parts of fructus cnidii, 35 parts of fructus rosae laevigatae, 35 parts of semen allii tuberose, 35 parts of morinda officinalis, 35 parts of herba cistanche, 46 parts of radix rehmanniae recen, 35 parts of radix cyathulae, 70 parts of herba epimedii, 35 parts of raspberry, 25 parts of ginseng, 16 parts of cornu cervi pantotrichum, 21 parts of hippocampus and 23 parts of fructus toosendan.
The preferred traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 250 parts of dodder, 150 parts of medlar, 45 parts of schisandra chinensis, 30 parts of fructus cnidii, 30 parts of cherokee rose fruit, 30 parts of semen allii tuberosi, 30 parts of morinda officinalis, 30 parts of cistanche, 45 parts of radix rehmanniae recen, 30 parts of medicinal cyathula root, 70 parts of epimedium, 30 parts of raspberry, 20 parts of ginseng, 19 parts of pilose antler, 20 parts of hippocampus and 20 parts of szechwan chinaberry fruit.
The medicament of the invention is in the form of decoction, capsules, tablets, granules, powder or pills.
In order to achieve the purpose of the invention, the traditional Chinese medicine composition is prepared into various pharmaceutical dosage forms, theoretically, the traditional Chinese medicine composition can be prepared into any dosage form according to a general preparation method, and the traditional Chinese medicine composition is preferably decoction, capsules, tablets, granules, powder or pills according to the applicable objects and indications. In order to make the above dosage forms possible, pharmaceutically acceptable excipients, such as: fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, bases, and the like. The filler comprises: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.; the disintegrating agent comprises: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crospolyvinylpyrrolidone, low-substituted hydroxypropylcellulose, croscarmellose sodium, etc.; the lubricant comprises: magnesium stearate, sodium lauryl sulfate, talc, silica, and the like; the suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, and the like; the adhesive comprises starch slurry, polyvinylpyrrolidone, hydroxypropyl methylcellulose, etc.; the sweetener comprises: saccharin sodium, aspartame, sucrose, sodium cyclamate, glycyrrhetinic acid, and the like; the flavoring agent comprises: sweeteners and various essences; the preservative comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its salts, benzalkonium bromide, chloroacetidine acetate, eucalyptus oil, etc.; the matrix comprises: PEG6000, PEG4000, insect wax, etc.
The preparation method of the capsule comprises the following steps:
a. weighing fructus Cnidii, semen Cuscutae, fructus Schisandrae chinensis, and herba Epimedii at a certain proportion, adding 6-10 times of 70% ethanol, reflux extracting for 1-3 times, each for 1-3 hr, filtering, mixing filtrates, recovering ethanol under reduced pressure to obtain ethanol extract;
b. mixing the medicinal material residues after the alcohol extraction in the step a with wolfberry fruit, radix rehmanniae recen, raspberry, cherokee rose fruit, Chinese chive seed, morinda officinalis and szechwan chinaberry fruit in proportion, adding 7-12 times of water, decocting for 1-3 times each time for 1-3 hours, filtering, mixing the filtrates, mixing with the alcohol extract obtained in the step a, and concentrating under reduced pressure until the relative density is 1.25-1.30 measured at 60 ℃ to obtain an extract;
c. weighing the ginseng, the pilose antler, the sea horse, the cistanche salsa and the medicinal cyathula root according to the proportion, crushing into fine powder, uniformly mixing with the extract obtained in the step b, drying at the temperature of 60-70 ℃, crushing, sieving and filling into capsules.
The preferred application of the medicament of the invention in the preparation of medicaments for inhibiting endometrial hyperplasia into simple hyperplasia.
The medicament has the advantages of small side effect, good effect, convenient use and low price in inhibiting endometrial hyperplasia.
Drawings
FIG. 1: effect of BZBS on high fat diet induced estrogen levels in Ovx/ApoE-/-mice after 12 weeks
FIG. 2: effect of BZBS on high fat diet induced uterine atrophy index (Ulters atrophy index (mg/g)) in Ovx/ApoE-/-mice after 12 weeks
Detailed Description
Example 1: preparation of capsules
The formula is as follows: 250g of dodder, 138g of medlar, 46g of schisandra chinensis, 35g of fructus cnidii, 35g of cherokee rose, 35g of semen allii tuberosi, 35g of morinda officinalis, 35g of cistanche, 46g of radix rehmanniae recen, 35g of medicinal cyathula root, 70g of epimedium herb, 35g of raspberry, 25g of ginseng, 16g of pilose antler, 21g of hippocampus and 23g of szechwan chinaberry fruit.
The preparation method comprises the following steps:
a. weighing fructus Cnidii, semen Cuscutae, fructus Schisandrae chinensis, and herba Epimedii at a certain proportion, adding 3208ml70% ethanol, reflux extracting for 3 times, each for 2 hr, filtering, mixing filtrates, and recovering ethanol under reduced pressure to obtain ethanol extract;
b. mixing the medicinal material residues after the alcohol extraction in the step a with wolfberry fruit, radix rehmanniae recen, raspberry, cherokee rose fruit, Chinese chive seed, morinda officinalis and szechwan chinaberry fruit in a certain proportion, adding 6732ml of water for decoction for 2 times, each time for 2 hours, filtering, mixing the filtrates, mixing with the alcohol extract obtained in the step a, and concentrating under reduced pressure until the relative density is 1.28 when the temperature is 60 ℃ to obtain an extract;
c. weighing the ginseng, the pilose antler, the sea horse, the cistanche and the medicinal cyathula root according to the proportion, crushing into fine powder, uniformly mixing with the extract obtained in the step b, drying at 60-70 ℃, crushing, sieving, and filling into capsules to obtain 757 capsules.
Example 2: preparation of tablets
The formula is as follows: 250g of dodder, 150g of medlar, 45g of schisandra chinensis, 30g of fructus cnidii, 30g of cherokee rose, 30g of semen allii tuberosi, 30g of morinda officinalis, 30g of cistanche, 45g of radix rehmanniae recen, 30g of medicinal cyathula root, 70g of epimedium herb, 30g of raspberry, 20g of ginseng, 19g of antler, 20g of hippocampus and 20g of szechwan chinaberry fruit.
The preparation method comprises the following steps:
a. weighing fructus Cnidii, semen Cuscutae, fructus Schisandrae chinensis, and herba Epimedii at a certain proportion, adding 2765ml70% ethanol, reflux extracting for 3 times, each for 1 hr, filtering, mixing filtrates, and recovering ethanol under reduced pressure to obtain ethanol extract;
b. mixing the medicinal material residues after the alcohol extraction in the step a with wolfberry fruit, radix rehmanniae recen, raspberry, cherokee rose fruit, Chinese chive seed, morinda officinalis and szechwan chinaberry fruit in a certain proportion, adding 5110ml of water for decocting for 1 time and 3 hours, filtering, mixing the filtrates, mixing with the alcohol extract obtained in the step a, and concentrating under reduced pressure until the relative density is 1.30 measured at 60 ℃ to obtain an extract;
c. weighing the ginseng, the pilose antler, the sea horse, the cistanche and the medicinal cyathula root according to the proportion, crushing into fine powder, uniformly mixing with the extract obtained in the step b, drying at 60-70 ℃, crushing, sieving, adding 1% of magnesium stearate, and tabletting to obtain 760 tablets.
Example 3: preparation of pills
The formula is as follows: 350g of dodder, 100g of medlar, 60g of schisandra chinensis, 20g of fructus cnidii, 50g of cherokee rose fruit, 50g of Chinese chive seed, 20g of morinda officinalis, 50g of cistanche, 60g of radix rehmanniae recen, 20g of medicinal cyathula root, 100g of epimedium herb, 20g of raspberry, 35g of ginseng, 10g of pilose antler, 35g of hippocampus and 15g of szechwan chinaberry fruit.
The preparation method comprises the following steps:
a. weighing fructus Cnidii, semen Cuscutae, fructus Schisandrae chinensis, and herba Epimedii at a certain proportion, adding 5300ml70% ethanol, reflux extracting for 1 time and 3 hr, filtering, mixing filtrates, recovering ethanol under reduced pressure to remove ethanol smell to obtain ethanol extract;
b. mixing the medicinal material residues after the alcohol extraction in the step a with wolfberry fruit, radix rehmanniae recen, raspberry, cherokee rose fruit, Chinese chive seed, morinda officinalis and szechwan chinaberry fruit in a proportion, adding 10140ml of water for decoction for 3 times, each time for 1 hour, filtering, mixing the filtrates, mixing with the alcohol extract obtained in the step a, and concentrating under reduced pressure until the relative density is 1.25 measured at 60 ℃ to obtain an extract;
c. weighing Ginseng radix, cornu Cervi Pantotrichum, Hippocampus, Cistanchis herba, and radix Cyathulae at a certain proportion, pulverizing into fine powder, mixing with the extract obtained in step b, drying at 60-70 deg.C, pulverizing, sieving, and making into pill, 320 g.
Example 4: preparation of granules
The formula is as follows: 150g of dodder, 200g of medlar, 30g of schisandra chinensis, 50g of fructus cnidii, 20g of cherokee rose fruit, 20g of Chinese chive seed, 50g of morinda officinalis, 20g of cistanche, 30g of radix rehmanniae recen, 50g of medicinal cyathula root, 40g of epimedium, 50g of raspberry, 15g of ginseng, 25g of pilose antler, 15g of hippocampus and 35g of szechwan chinaberry fruit.
The preparation method comprises the following steps:
a. weighing fructus Cnidii, semen Cuscutae, fructus Schisandrae chinensis, and herba Epimedii at a certain proportion, adding 2430ml70% ethanol, reflux extracting for 2 times, each for 1.5 hr, filtering, mixing filtrates, recovering ethanol under reduced pressure to obtain ethanol extract;
b. mixing the residue of the medicinal materials extracted by the alcohol in the step a with the other medicinal materials in a proportion, adding 8800ml of water, decocting for 3 times, 1 hour each time, filtering, mixing the filtrates, mixing with the alcohol extract obtained in the step a, and concentrating under reduced pressure until the relative density is 1.29 measured at 60 ℃ to obtain an extract;
c. and c, uniformly mixing the extract obtained in the step b with 300g of dextrin and 200g of sucrose powder, drying at 60-70 ℃, crushing, sieving and granulating to obtain 700g of granules.
Example 5: preparation of powder
The formula is as follows: 250g of dodder, 150g of medlar, 45g of schisandra chinensis, 30g of fructus cnidii, 30g of cherokee rose, 30g of semen allii tuberosi, 30g of morinda officinalis, 30g of cistanche, 45g of radix rehmanniae recen, 30g of medicinal cyathula root, 70g of epimedium herb, 30g of raspberry, 20g of ginseng, 19g of antler, 20g of hippocampus and 20g of szechwan chinaberry fruit.
The preparation method comprises the following steps: weighing the traditional Chinese medicinal materials in the formula according to the proportion, mixing and crushing the traditional Chinese medicinal materials into fine powder to obtain 823g of powder.
Example 6: preparation of decoction
The formula is as follows: 250g of dodder, 150g of medlar, 45g of schisandra chinensis, 30g of fructus cnidii, 30g of cherokee rose, 30g of semen allii tuberosi, 30g of morinda officinalis, 30g of cistanche, 45g of radix rehmanniae recen, 30g of medicinal cyathula root, 70g of epimedium herb, 30g of raspberry, 20g of ginseng, 19g of antler, 20g of hippocampus and 20g of szechwan chinaberry fruit.
The preparation method comprises the following steps: weighing traditional Chinese medicinal materials in a formula according to a certain proportion, adding water until the traditional Chinese medicinal materials are submerged, soaking for 15 minutes, heating until the water is boiled, continuing decocting for 30 minutes with slow fire, filtering, adding water again until the medicinal materials are submerged, decocting for 30 minutes again, filtering, and combining the filtrates to obtain 4320g decoction.
Test example:
to elucidate the effect of the present invention on inhibiting endometrial hyperplasia, the following experiment was conducted using example 1 (hereinafter referred to as the present invention drug or BZBS):
1. animal grouping and Experimental design
60 female homozygote ApoE-/-mice and 15 female C57BL/6J mice, both 6-8 weeks old, were purchased from Jiangsu Jiejiaokang Biotech Inc. The animal feeding conditions are 22 deg.C, 12h/12h light and dark circadian rhythm, no food limit and water limit. 3 days after adaptive feeding, ApoE-/-mice received bilateral ovariectomy (surgical menopausal model) and C57BL/6J mice were given sham surgery as a Control group (Control).
After 1 week, ApoE-/-mice were randomized into 4 groups (n = 15/group): model group (Model) (high fat diet +0.5% sodium carboxymethyl cellulose (CMC) gavage), G1 group (high fat diet + G10.2ug/d subcutaneous injection), BZBS high dose group (HD-BZ) (high fat diet + BZBS 2.8G/kg/d gavage), BZBS low dose group (LD-BZ) (high fat diet + BZBS 1.4G/kg/d gavage), 15C 57BL/6J mice were Control group (Control) (normal diet + CMC gavage). Normal diet (standard diet) was purchased from mohr feed limited (M10001, Chengdu), high fat diet (no phytoestrogen, 40% fat, 1.25% cholesterol, 0.5% bile acid) was purchased from Research diet ltd (D12109C, new jersey, usa). Animals were sacrificed after 12 weeks for subsequent experiments.
2. Results
The significantly reduced estradiol (E2) levels in the Model group (Model) compared to the Control group (Control) confirmed that post-menopausal status was achieved as expected after bilateral ovariectomy. The levels of the positive drug G1 group and the Model group (Model) E2 did not change significantly (FIG. 1). In contrast, the E2 concentrations were elevated in both the HD-BZ and LD-BZ groups, indicating that BZBS has estrogen-like effects.
The uterine atrophy index (uterine weight (mg)/body weight (g)), Ovx/ApoE-/-mice each index was significantly lower than the control group (C57BL/6 mice). (FIG. 2, Table 1)
3. Conclusion
The medicine can effectively inhibit endometrial hyperplasia, has the same effective rate as a positive control group, and particularly has better effect on simple endometrial hyperplasia caused by long-term stimulation of estrogen without progesterone antagonism due to menopause.
Claims (8)
1. The application of a traditional Chinese medicine composition in preparing a medicine for inhibiting endometrial hyperplasia is characterized in that the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 150-350 parts of semen cuscutae, 100-200 parts of fructus lycii, 30-60 parts of fructus schisandrae, 20-50 parts of fructus cnidii, 20-50 parts of fructus rosae laevigatae, 20-50 parts of semen allii tuberosi, 20-50 parts of morinda officinalis, 20-50 parts of cistanche, 30-60 parts of radix rehmanniae recen, 20-50 parts of radix cyathulae, 40-100 parts of herba epimedii, 20-50 parts of raspberry, 15-35 parts of ginseng, 10-25 parts of cornu cervi pantotrichum, 15-35 parts of hippocampus and 15-35 parts of fructus toosendan.
2. The application of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 150 parts of semen cuscutae, 200 parts of fructus lycii, 30 parts of fructus schizandrae, 50 parts of fructus cnidii, 20 parts of fructus rosae laevigatae, 20 parts of semen allii tuberose, 50 parts of morinda officinalis, 20 parts of herba cistanche, 30 parts of radix rehmanniae recen, 50 parts of radix cyathulae, 40 parts of herba epimedii, 50 parts of raspberry, 15 parts of ginseng, 25 parts of cornu cervi pantotrichum, 15 parts of hippocampus and 35 parts of fructus toosendan.
3. The application of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 350 parts of semen cuscutae, 100 parts of fructus lycii, 60 parts of fructus schizandrae, 20 parts of fructus cnidii, 50 parts of fructus rosae laevigatae, 50 parts of semen allii tuberose, 20 parts of morinda officinalis, 50 parts of herba cistanche, 60 parts of radix rehmanniae recen, 20 parts of radix cyathulae, 100 parts of herba epimedii, 20 parts of raspberry, 35 parts of ginseng, 10 parts of cornu cervi pantotrichum, 35 parts of hippocampus and 15 parts of fructus toosendan.
4. The application of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 250 parts of semen cuscutae, 138 parts of fructus lycii, 46 parts of fructus schizandrae, 35 parts of fructus cnidii, 35 parts of fructus rosae laevigatae, 35 parts of semen allii tuberose, 35 parts of morinda officinalis, 35 parts of herba cistanche, 46 parts of radix rehmanniae recen, 35 parts of radix cyathulae, 70 parts of herba epimedii, 35 parts of raspberry, 25 parts of ginseng, 16 parts of cornu cervi pantotrichum, 21 parts of hippocampus and 23 parts of fructus toosendan.
5. The application of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 250 parts of dodder, 150 parts of medlar, 45 parts of schisandra chinensis, 30 parts of fructus cnidii, 30 parts of cherokee rose fruit, 30 parts of semen allii tuberosi, 30 parts of morinda officinalis, 30 parts of cistanche, 45 parts of radix rehmanniae recen, 30 parts of medicinal cyathula root, 70 parts of epimedium, 30 parts of raspberry, 20 parts of ginseng, 19 parts of pilose antler, 20 parts of hippocampus and 20 parts of szechwan chinaberry fruit.
6. The use according to any one of claims 1 to 5, wherein the medicament is in the form of a decoction, capsule, tablet, granule, powder or pill.
7. The process for preparing a capsule according to claim 6, comprising the steps of:
a. weighing fructus Cnidii, semen Cuscutae, fructus Schisandrae chinensis, and herba Epimedii at a certain proportion, adding 6-10 times of 70% ethanol, reflux extracting for 1-3 times, each for 1-3 hr, filtering, mixing filtrates, recovering ethanol under reduced pressure to obtain ethanol extract;
b. mixing the medicinal material residues after the alcohol extraction in the step a with wolfberry fruit, radix rehmanniae recen, raspberry, cherokee rose fruit, Chinese chive seed, morinda officinalis and szechwan chinaberry fruit in proportion, adding 7-12 times of water, decocting for 1-3 times each time for 1-3 hours, filtering, mixing the filtrates, mixing with the alcohol extract obtained in the step a, and concentrating under reduced pressure until the relative density is 1.25-1.30 measured at 60 ℃ to obtain an extract;
c. weighing the ginseng, the pilose antler, the sea horse, the cistanche salsa and the medicinal cyathula root according to the proportion, crushing into fine powder, uniformly mixing with the extract obtained in the step b, drying at the temperature of 60-70 ℃, crushing, sieving and filling into capsules.
8. The use according to any one of claims 1 to 5, wherein said inhibition of endometrial hyperplasia is simple hyperplasia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010099158.4A CN113332374A (en) | 2020-02-18 | 2020-02-18 | Application of traditional Chinese medicine composition in preparation of medicine for inhibiting endometrial hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010099158.4A CN113332374A (en) | 2020-02-18 | 2020-02-18 | Application of traditional Chinese medicine composition in preparation of medicine for inhibiting endometrial hyperplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113332374A true CN113332374A (en) | 2021-09-03 |
Family
ID=77466975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010099158.4A Pending CN113332374A (en) | 2020-02-18 | 2020-02-18 | Application of traditional Chinese medicine composition in preparation of medicine for inhibiting endometrial hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113332374A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101584797A (en) * | 2008-05-22 | 2009-11-25 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome |
| CN103417799A (en) * | 2012-05-22 | 2013-12-04 | 石家庄以岭药业股份有限公司 | Applications of a traditional Chinese medicine composition in preparing medicines treating anaemia |
-
2020
- 2020-02-18 CN CN202010099158.4A patent/CN113332374A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101584797A (en) * | 2008-05-22 | 2009-11-25 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome |
| CN103417799A (en) * | 2012-05-22 | 2013-12-04 | 石家庄以岭药业股份有限公司 | Applications of a traditional Chinese medicine composition in preparing medicines treating anaemia |
Non-Patent Citations (2)
| Title |
|---|
| 健客网: "八子补肾胶囊对性激素水平的影响是怎样的？", pages 1, Retrieved from the Internet <URL:https://www.jianke.com/a/20141231/1204040.html> * |
| 黄丹: "络病理论指导八子补肾胶囊干预绝经后动脉粥样硬化理论探讨与作用机制研究", 中国博士学位论文全文数据库 医药卫生科技辑, no. 08, pages 057 - 82 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101584797A (en) | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome | |
| CN103239590A (en) | Traditional Chinese medicine composition as well as preparation and application thereof | |
| CN102038915B (en) | Traditional Chinese medicament for treating hysteromyoma and preparation method thereof | |
| WO2022160520A1 (en) | Pharmaceutical composition for treating cervical disc herniation, and preparation method therefor and application thereof | |
| CN105287812A (en) | Medicine composition for treating irritable bowel syndromes and application of medicine composition | |
| CN1318058C (en) | Method for preparing concentrated pill for treating mammary gland proliferation disease | |
| CN101664533B (en) | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method | |
| CN113332374A (en) | Application of traditional Chinese medicine composition in preparation of medicine for inhibiting endometrial hyperplasia | |
| CN101897855A (en) | Medicament for treating uterine myoma | |
| CN100566706C (en) | A kind of Chinese medicinal capsule for the treatment of cyclomastopathy and preparation method thereof | |
| CN102038821B (en) | Method for preparing medicinal composition for treating dysmenorrhea | |
| CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
| CN103127272A (en) | Chinese medicinal preparation for treating breast disease and preparation method thereof | |
| WO2022160519A1 (en) | Traditional chinese medicine composition for treating cervicogenic shoulder and back pain, and preparation method therefor and use thereof | |
| CN102579761A (en) | Application of traditional Chinese medicine beauty composition in preparation of medicament for adjusting women hormonal equilibrium | |
| CN101670080A (en) | Chinese medicinal composition for chronic gastritis and preparation process thereof | |
| CN117959361B (en) | Pharmaceutical composition for strengthening tendons and bones and preparation method thereof | |
| CN112402542A (en) | Application of traditional Chinese medicine composition in preparation of blood fat reducing medicine | |
| CN112316046B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating atherosclerosis | |
| CN103417763B (en) | One treats osteoporotic pharmaceutical composition and its production and use | |
| CN102018849A (en) | Traditional Chinese medicine composition for preventing irregular menstruation and preparation method thereof | |
| CN102671113B (en) | Traditional Chinese medicine composition for treating nodules of breasts and preparation method of traditional Chinese medicine composition | |
| CN101468124A (en) | Chinese medicinal composition for preventing and treating menoxenia and method for preparing the same | |
| CN107898974B (en) | Traditional Chinese medicine for treating dysmenorrhea of women | |
| CN113332375A (en) | Application of traditional Chinese medicine composition in preparation of GPER1 receptor agonist medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |